Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
Authors:
- Katarina Steen CarlssonKCKatarina Steen Carlsson
- Ulf PerssonUPUlf Persson
- Marcus Schmitt-EgenolfMarcus Schmitt-Egenolf
- 1 January 2012
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 225 (4) , 326-332
Abstract
Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Pso-riasis, PsoReg. Outcomes of biological-naïve patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI ≥10 and/or PASI ≥10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores.Keywords
This publication has 24 references indexed in Scilit:
- Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical reviewBMC Medical Research Methodology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literatureJournal of the European Academy of Dermatology and Venereology, 2010
- When can RCTs and observational intervention studies mislead us and what can we do about it?International Journal Of Clinical Practice, 2009
- Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL studyJournal of the European Academy of Dermatology and Venereology, 2009
- The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical resultsBritish Journal of Dermatology, 2008
- Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in GermanyDermatology, 2008
- Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2007
- Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trialJournal of Dermatological Treatment, 2007
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990